Insight Molecular Diagnostics Completes Key Milestones Advancing GraftAssureDx Toward FDA Submission

Rhea-AI Summary

Insight Molecular Diagnostics (Nasdaq: IMDX) completed key milestones in February 2026 advancing GraftAssureDx toward an FDA De Novo IVD submission. Milestones include a three-site reproducibility study, collection of sufficient clinical samples based on a projected 25–30% rejection rate, and ISO 13485 certification (Feb. 26).

Internal analytical work is nearly complete: about 11,660 of 12,000 instrument and assay cycles finished (roughly 340 remain). Certification enables planned U.K. and EU submissions and supports commercial manufacturing readiness in 2026.

Positive

• Three-site reproducibility study completed (Tampa General, Mayo Clinic, Baylor)
• Collected sufficient clinical samples based on 25%–30% projected rejection rate
• Achieved ISO 13485 certification on Feb. 26, 2026
• Approximately 11,660 of 12,000 instrument/assay cycles completed

Negative

• About 340 instrument and assay cycles remain to complete analytical package
• Some clinical activities remain outside company control and may delay submission

News Market Reaction – IMDX

+10.32%

9 alerts

+10.32% News Effect

+4.8% Peak in 3 hr 9 min

+$18M Valuation Impact

$189M Market Cap

0.5x Rel. Volume

On the day this news was published, IMDX gained 10.32%, reflecting a significant positive market reaction. Argus tracked a peak move of +4.8% during that session. Our momentum scanner triggered 9 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $18M to the company's valuation, bringing the market cap to $189M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Instrument and assay cycles: 12,000 cycles Remaining cycles: 340 cycles Projected rejection rate (low): 25% +5 more

8 metrics

Instrument and assay cycles 12,000 cycles Total cycles needed to support FDA submission package

Remaining cycles 340 cycles Approximate remaining internal analytical performance study cycles

Projected rejection rate (low) 25% Lower bound of projected organ rejection rate underlying sample projections

Projected rejection rate (high) 30% Upper bound of projected organ rejection rate underlying sample projections

Transplant testing market $2 billion-plus Addressable market for regulated transplant rejection testing cited for GraftAssureDx

ISO 13485 certification date Feb. 26 Final ISO 13485 certification enabling U.K. and E.U. submissions

Publication year 2026 Company targets global submissions and commercialization activities during 2026

Trial sites in reproducibility study 3 sites Tampa General, Mayo Clinic, and Baylor Scott & White Health involved

Market Reality Check

Price: $5.45 Vol: Volume 214,882 is 2.48x t...

high vol

$5.45 Last Close

Volume Volume 214,882 is 2.48x the 20-day average of 86,502, indicating elevated trading activity. high

Technical Price at $4.94 is trading above the 200-day MA of $4.71, despite a -17.8% 24h move and sitting 41.95% below its 52-week high.

Peers on Argus

IMDX fell 17.8% while key peers were mixed. Only PRE showed momentum scanner act...

1 Up

IMDX fell 17.8% while key peers were mixed. Only PRE showed momentum scanner activity and was up, highlighting that today’s downward move appears stock-specific rather than part of a diagnostics-sector rotation.

Previous Clinical trial Reports

2 past events · Latest: Jan 05 (Positive)

Same Type Pattern 2 events

Date	Event	Sentiment	Move	Catalyst
Jan 05	Clinical trial update	Positive	+4.3%	Year-end progress on GraftAssureDx and nearing FDA de novo submission.
Sep 08	Trial initiation	Positive	+0.4%	First patient enrolled and expansion to 10 centers for GraftAssureDx trial.

Pattern Detected

Clinical trial updates for GraftAssureDx have historically been followed by modest positive moves, suggesting the stock has typically responded constructively to similar milestones.

Recent Company History

Recent history around GraftAssureDx shows steady clinical and regulatory progress. On Sep 8, 2025, IMDX announced first patient enrollment and expansion to 10 transplant centers, targeting up to 125 patients and a $1 billion market. On Jan 5, 2026, it reported ~95% completion of its planned FDA IVD de novo submission work and broad engagement across 20 global centers. Today’s announcement continues that theme with additional milestones toward FDA submission and international filings.

Historical Comparison

+2.4% avg move · Over the past two clinical-trial updates, IMDX’s average 24h move was 2.37% on generally positive Gr...

clinical trial

+2.4%

Average Historical Move clinical trial

Over the past two clinical-trial updates, IMDX’s average 24h move was 2.37% on generally positive GraftAssureDx milestones, framing this as another step in that progression.

Clinical milestones have progressed from initial GraftAssureDx trial enrollment and site expansion in 2025 to near-completion of FDA de novo submission work and, now, completion of key reproducibility and sample-collection steps ahead of U.S., U.K. and E.U. submissions.

Market Pulse Summary

The stock surged +10.3% in the session following this news. A strong positive reaction aligns with t...

Analysis

The stock surged +10.3% in the session following this news. A strong positive reaction aligns with the company’s pattern of constructive responses to GraftAssureDx milestones, where past clinical updates saw average moves around 2.37%. Investors reviewing this news may weigh the completed reproducibility work, near-finished analytical studies, and ISO 13485 certification against execution risks in final FDA review and global rollout, as well as the stock’s position 41.95% below its 52-week high.

Key Terms

in vitro diagnostic, de novo submission, iso 13485, donor-derived cell-free dna, +3 more

7 terms

in vitro diagnostic medical

"planned in vitro diagnostic (IVD) De Novo submission to the U.S. Food and Drug Administration"

In vitro diagnostics are tests, instruments and kits used to analyze samples taken from the body—such as blood, urine or swabs—outside the body (in a lab or cartridge) to detect disease, infections, genetic traits or other biological signs. Investors care because these products generate sales, recurring revenue from consumable test kits, and value that hinges on test accuracy, regulatory approvals and reimbursement policies; like a home pregnancy test but for many medical conditions.

de novo submission regulatory

"for its planned in vitro diagnostic (IVD) De Novo submission to the U.S. Food and Drug Administration"

A de novo submission is the process of formally requesting approval from a regulatory authority to introduce a new product or technology that has not been previously authorized. It is like applying for permission to launch a completely new idea that hasn't been approved before. For investors, it signals that a company is seeking official approval to bring an innovative product to market, which can impact its growth prospects and potential risks.

iso 13485 regulatory

"Company achieved final ISO 13485 certification on Feb. 26, enabling U.K. and E.U. regulatory submissions"

ISO 13485 is an international quality management standard for organizations that design, produce, or service medical devices. Think of it as a factory’s rulebook and checklist that helps ensure products are safe, consistently made, and meet regulatory rules worldwide. For investors, certification signals lower operational and regulatory risk, easier market access, and greater reliability of a company’s medical products and supply chain — similar to buying from a trusted, inspected supplier.

donor-derived cell-free dna medical

"technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA)"

Donor-derived cell-free DNA is fragments of DNA shed by a transplanted organ into the recipient’s bloodstream. Measuring its level is like checking a smoke alarm: rising amounts can warn of organ injury or immune rejection before symptoms appear. Investors track this biomarker because tests and treatments that detect or lower it can change clinical decisions, demand for diagnostic services, and the economic outlook for transplant-related healthcare products.

laboratory-developed test medical

"GraftAssureCore - The company's laboratory-developed test (LDT), currently reimbursed by CMS"

A laboratory-developed test is a diagnostic test that a single clinical laboratory designs, builds and uses in its own facility rather than buying from an outside manufacturer; think of it as a custom recipe made and run in-house for diagnosing disease. Investors care because these tests can be quicker to bring to market and create a revenue stream for labs, but they also carry regulatory and quality-risk differences that can affect demand, reimbursement and legal exposure.

research-use-only technical

"GraftAssureIQ - A research-use-only (RUO) kit intended and labeled for non-clinical applications"

Products labeled “research-use-only” are tools, tests, or reagents sold for laboratory experiments and scientific study, not approved for diagnosing, treating, or making clinical decisions about patients. For investors, the label matters because it limits where and how a product can be sold, keeps regulatory burdens lower but also narrows market size and revenue potential until the product is validated and approved for clinical or commercial use — like a prototype that can’t yet be sold in stores.

clia-certified regulatory

"performed at iMDx's CLIA-certified laboratory in Nashville"

CLIA-certified means a laboratory has passed U.S. federal standards for performing tests on human samples, showing its results are accurate, reliable and timely. For investors this matters because certification is often required to sell clinical test services, bill insurers, win hospital or physician partnerships and avoid regulatory penalties — much like a restaurant passing a health inspection or a car getting a safety sticker before it can be sold.

AI-generated analysis. Not financial advice.

• Three-site reproducibility study completed by Tampa General Hospital, Mayo Clinic, and Baylor Scott & White Health
• Sufficient clinical samples collected to support statistical analysis and FDA submission
• Company achieved final ISO 13485 certification on Feb. 26, enabling U.K. and E.U. regulatory submissions
  

NASHVILLE, Tenn., March 03, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc. (Nasdaq: IMDX) (“iMDx”) today announced that in February the company completed several major milestones to support the GraftAssureDx™ test kit clinical trial for its planned in vitro diagnostic (IVD) De Novo submission to the U.S. Food and Drug Administration (FDA) and also received its ISO 13485 certification.

Beginning in 2026, iMDx seeks to deliver the industry-leading molecular diagnostic test kit for clinical use that expands and improves access to organ health testing for kidney transplant patients. The company expects that enabling localized testing will deliver new value in the roughly $2 billion-plus addressable market for regulated transplant rejection testing.

Milestones completed in February include the conclusion of the three-site reproducibility study for GraftAssureDx, performed at Tampa General Hospital, Mayo Clinic and Baylor Scott & White Health, the collection of what the company believes is sufficient clinical samples to execute its submission, and the receipt of ISO 13485 certification, described in more detail below.

The company is rapidly finishing the remainder of its internal analytical performance studies. Of the approximately 12,000 instrument and assay cycles needed to support the FDA submission package, about 340 remain.

The IVD submission can be broken down into two categories – (1) the clinical validation studies that happen at the clinical trial sites, and (2) the internal analytical performance studies, performed at the company’s Nashville laboratory.

On the clinical validation, iMDx has received what it believes should be sufficient clinical samples to execute the FDA submission. Our clinical trial site partners are continuing to collect and test those patient samples, as well as perform patient biopsies to confirm that the assay performed as it should. We are pleased with the level of engagement at these major transplant hospitals and are working closely with our site partners to move as efficiently as possible, recognizing that certain clinical activities remain outside of our direct control.

A reproducibility study at three clinical trial sites, Tampa General Hospital, Mayo Clinic, and Baylor Scott & White Health, is also part of our analytical validation. This reproducibility study was finished at the clinical trial sites on February 23, representing the conclusion of a major milestone.

“Our clinical trial sites have now collected the needed number of samples to finalize the clinical trial part for our FDA submission, based on the projected 25% to 30% organ rejection rate, and those results are being gathered at the sites,” said iMDx Chief Science Officer Dr. Ekkehard Schuetz. “This combined with the reproducibility study conclusion represents two major milestones, and we are thrilled about the collaboration with our clinical partners to help us achieve our goal of finalizing our de-novo submission.”

Regarding internal analytical performance studies, as noted above, we are working diligently to complete the large-scale precision and repeatability study using our final IVD software combined with the finalized Bio-Rad equipment and reagents.

“We feel confident about every IVD work stream that is within our control, and we are very close to executing our submission to the FDA,” said iMDx Chief Technology Officer Johnson Chiang. “We are proud of our team’s ability to manage complexity and coordinate with multiple stakeholders, including our kit manufacturer, software vendor, the clinical trial sites, and Bio-Rad, which has also been working tirelessly to support a timely submission.”

Preparing for global manufacturing, it is also worth noting that achieving ISO 13485 means that our independent European auditor, TÜV SÜD, has certified that iMDx runs its operations under a disciplined, regulator-aligned quality management system. We believe that this certification showcases reduced risk of surprises in the FDA review, as well as reduced quality risk regarding future manufacturing and commercialization.

The ISO13485 certification at the end of February also immediately paves the way for an IVD submission in the U.K., which then will be followed by an IVD-R submission for the EU during 2026, which is also already in preparation.

iMDx Transplant Products and Product Candidates in Development

iMDx's flagship transplant testing technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). The company's scientists in Germany and the U.S. have played a critical role over the past decade in developing the science that helped establish dd-cfDNA as a trusted biomarker of transplant rejection. iMDx is commercializing this technology using a market-disruptive business strategy. Under the GraftAssure^TM brand, iMDx's transplant diagnostics include the following:

• GraftAssureCore - The company's laboratory-developed test (LDT), currently reimbursed by CMS and performed at iMDx's CLIA-certified laboratory in Nashville.
• GraftAssureIQ - A research-use-only (RUO) kit intended and labeled for non-clinical applications.
• GraftAssureDx - The in vitro diagnostic (IVD) kit currently in development for use in clinical decision-making.
  
  

About Insight Molecular Diagnostics, Inc.

Insight Molecular Diagnostics is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. Investors may visit https://investors.imdxinc.com/ for more information.

GraftAssureCore^TM,GraftAssureIQ^TM, GraftAssureDx^TM, VitaGraft^TM, GraftAssure^TM, DetermaIO^TM, and DetermaCNI^TM are trademarks of Insight Molecular Diagnostics Inc.

Forward-Looking Statements

Any statements that are not historical fact (including, but not limited to, statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates,” “may,” and similar expressions) are forward-looking statements. These statements include those pertaining to, among other things, the company’s expected FDA submission, future plans to submit in the UK and EU, anticipated added value of the Company’s GraftAssureDx kit to the roughly $2 billion-plus addressable market, future manufacturing and commercialization and other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of diagnostic tests or products, uncertainty in the results of clinical trials or regulatory approvals, the capacity of Insight Molecular Diagnostics’ third-party supplied blood sample analytic system to provide consistent and precise analytic results on a commercial scale, potential interruptions to supply chains, the need and ability to obtain future capital, maintenance of intellectual property rights in all applicable jurisdictions, obligations to third parties with respect to licensed or acquired technology and products, the need to obtain third party reimbursement for patients’ use of any diagnostic tests Insight Molecular Diagnostics or its subsidiaries commercialize in applicable jurisdictions, and risks inherent in strategic transactions such as the potential failure to realize anticipated benefits, legal, regulatory or political changes in the applicable jurisdictions, accounting and quality controls, potential greater than estimated allocations of resources to develop and commercialize technologies, or potential failure to maintain any laboratory accreditation or certification. Actual results may differ materially from the results anticipated in these forward-looking statements and accordingly such statements should be evaluated together with the many uncertainties that affect the business of Insight Molecular Diagnostics, particularly those mentioned in the “Risk Factors” and other cautionary statements found in Insight Molecular Diagnostics’ Securities and Exchange Commission (SEC) filings, which are available from the SEC’s website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Insight Molecular Diagnostics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

Investor Contact:

Alexandra Grossman

LifeSci Advisors LLC

alex@lifesciadvisors.com

FAQ

What FDA submission progress did Insight Molecular Diagnostics (IMDX) report on March 3, 2026?

iMDx reported completion of a three-site reproducibility study and sufficient clinical sample collection for its De Novo IVD submission. According to the company, internal analytical studies are nearly done with about 340 instrument/assay cycles remaining.

How does the ISO 13485 certification on Feb. 26, 2026 affect IMDX's regulatory plans?

ISO 13485 certification enables regulatory submissions and manufacturing readiness in Europe and the U.K. According to the company, the certification immediately paves the way for a U.K. IVD filing and supports an EU IVD-R submission planned in 2026.

What clinical sites participated in the GraftAssureDx reproducibility study for IMDX?

The reproducibility study was completed at Tampa General Hospital, Mayo Clinic, and Baylor Scott & White Health. According to the company, these three sites concluded the study on Feb. 23, 2026, marking a major milestone for clinical validation.

How many instrument and assay cycles remain before IMDX can finalize its FDA submission?

About 340 of roughly 12,000 instrument and assay cycles remain to complete the analytical performance studies. According to the company, approximately 11,660 cycles are finished and the remainder is being finalized in Nashville.

What market opportunity does GraftAssureDx target and how might localized testing help shareholders?

GraftAssureDx targets a roughly $2 billion-plus addressable market for regulated transplant rejection testing. According to the company, localized IVD testing aims to expand access to organ health testing for kidney transplant patients and support commercialization.